Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

OBJECTIVES: In the Phase I/III IMpower133 study, first-line atezolizumab plus carboplatin and etoposide (CP/ET) treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved overall survival (OS) and progression-free survival versus placebo plus CP/ET. We explored patient and disease characteristics associated with long-term survival in IMpower133, and associations of differential gene expression and SCLC-A (ASCL1-driven), SCLC-N (NEUROD1-driven), SCLC-P (POU2F3-driven), and SCLC-inflamed (SCLC-I) transcriptional subtypes with long-term survival. MATERIALS AND METHODS: Patients with previously untreated ES-SCLC were randomized 1:1 to four 21-day cycles of CP/ET with atezolizumab or placebo. Long-term survivors (LTS) were defined as patients who lived 

• Liu, S. V.
• Mok, T. S. K.
• Nabet, B. Y.
• Mansfield, A. S.
• De Boer, R.
• Losonczy, G.
• Sugawara, S.
• Dziadziuszko, R.
• Krzakowski, M.
• Smolin, A.
• Hochmair, M. J.
• Garassino, M. C.
• Gay, C. M.
• Heymach, J. V.
• Byers, L. A.
• Lam, S.
• Cardona, A.
• Morris, S.
• Adler, L.
• Shames, D. S.
• Reck, M.